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S U P P O R T I N G I N F O R M A T I O N
Additional supporting information may be found online in the Supporting Information section at the end of the article. and AR with a 4-week recall period. In a time where the use of mobile devices has grown, a new modality to monitor patients is at our dis-
posal. An electronic CARAT questionnaire allows clinicians to gain more insight into the period between visits and therefore could be a convenient and reliable alternative to the use of the current paper version of the CARAT. The main purpose of this study was to investigate the psychometric properties of the CARAT with 1-week recall period as paper version (CARATp1) and as electronic version (CARATe1).
This is a diagnostic study with repeated measurements in four consecutive weeks. The study population consisted of consecutive Dutch primary care asthma patients who were referred by their general practitioner to the asthma/COPD service. 6 Inclusion criteria were As percentage of predicted; nonimputed data were used for the descriptive statistics.
T A B L E 1 Baseline characteristics as follows: age 18-80 years and asthma diagnosis (made by a pulmonologist based on lung function tests including reversibility and selfreported questionnaires). Participation was voluntary, all patients received oral and written information about the study and all patients signed informed consent (study approved by the local medical ethics committee (METc 2014/578)).
In the period between January and August 2015, patients completed the following questionnaires on paper at baseline: CARATp1, ARIA 2 questions, Visual Analogue Scale (VAS) 7 on airway symptoms, ACQ 8 and GINA 9 questions. For 4 weeks (T1, T2, T3 and T4), the patients completed the CARATe1 each Monday and the CARATp1 every Tuesday. In the last week, the patients completed also the original CARAT on paper (CARATp4) and an evaluation form (see Table S1 , Data S1). The CARAT contains ten questions concerning asthma symptoms (asthma domain) and AR symptoms (AR domain)
in the previous 4 weeks and is administered on paper. [3] [4] [5] The only difference between the CARATp4 and the CARATp1 was the shorter recall period. The CARATe1 is an electronic application for smart devices developed by AstraZeneca. It shows, after a short instruction screen, the CARAT questions on ten consecutive screens.
The construct validity was calculated using Spearman correlation coefficient (ρ). The CARATp1 at baseline was compared with ARIA, VAS, GINA and ACQ (ρ 0.6-0.8 was expected). 10 The correlation between CARATp1 and CARATe1 was calculated using Spearman correlation coefficient (ρ > 0.80 was expected). The internal consistency of CARATp1 and CARATe1 was determined using Cronbach's alpha (α 0.70-0.95 was expected). 10 The test-retest reliability of with CARATp4 were calculated (ρ > 0.80 was expected). Statistical analysis was performed using SPSS 25 (IBM, Chicago, USA). Missing data were assumed to be missing at random and replaced using a multiple imputation procedure (see Data S1).
In this study, 123 patients were included for analyses and 23% of the AR patients reported intermitting AR (Table 1 ) (see Data S1). Construct validity of the CARATp1 was shown by correlation coefficients within the expected range (ρ 0.584-0.718) with VAS, ACQ, ARIA and GINA. As expected, the highest correlation coefficients were found (a)
between AR domain of the CARAT and ARIA and VAS upper airway symptoms; and (b) between the asthma domain of the CARAT and GINA, ACQ and VAS lower airway symptoms (Table 2 ).
CARATp1 was highly correlated with CARATe1 (ρ 0.856-0.923).
Internal consistency of both CARATp1 and CARATe1 was good The majority of patients (93%) considered the electronic version to be easy or very easy to complete and only 6% preferred the paper version (see Figure S1 , Data S1).
This study found that the paper and electronic CARAT questionnaires with a 1-week recall period are valid and reliable, with comparable psychometric properties as the original CARAT4p. 3, 4 CARATp1 and CARATe1 were strongly correlated with the original CARAT4p. Also, CARATp1 and CARATe1 were closely correlated.
Moreover, the patients participating in this study considered the Interestingly, the correlation of the CARATp4 with the scores in individual weeks of the CARATp1 and the CARATe1 showed increasing correlation coefficients. In both cases, the correlation with the CARATp4 tends to rise as the questionnaires with 1-week recall are completed closer in time to when the CARATp4 was completed.
This may suggest that recent weeks play a more prominent role in the assessment of the patient when completing the CARATp4 than the first weeks in the recall period. One may argue to prefer the CARAT with 1-week recall period to minimize recall bias.
The CARATe1 was viewed favourably by most patients in this study. Only 6% preferred the CARATp1. This may not be surprising considering the high level of integration in daily life of smart devices. However, one patient considered the CARATe1 to be very hard to complete (65-year-old woman). Although this is just one case, it shows that the paper version of the CARAT should not be fully discarded (see Data S1).
Future research should focus on the calculation of the CARAT's cut points to differentiate between controlled and uncontrolled asthma and AR. In addition, the effects of implementation of the CARATe1 on control and management in primary care should be investigated. This study showed that both new versions of the CARAT could be used as convenient tools for both patient and clinician to gain more insight into the control of asthma and AR.
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S U P P O R T I N G I N F O R M A T I O N
To our knowledge, this is the first study to clearly document longitudinal changes in respiratory allergen sensitization and identify factors associated with DNS to Af. Notably, IgE positivity frequencies against Af extract and rAsp f 1 increased considerably. Our findings from component-based IgE measurements indicate genuine changes in sensitization profiles to panels of respiratory allergens.
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